Fluidra (BME:FDR) Launches A Buyback And Posts Higher Revenue, Is It Undervalued?
Fluidra (BME:FDR) has drawn renewed attention to its stock after announcing a share repurchase program of up to €40 million, alongside half-year 2026 results that report higher revenue and lower net income.
See our latest analysis for Fluidra.
Despite the new buyback plan and Fluidra’s latest half year results, recent momentum is mixed, with a 7 day share price return of 5.3%, a year to date share price return that is down 15.5%, and a 1 year total shareholder return that is down 8.4%.
If this kind of capital allocation move has caught your eye, it can be helpful to broaden your watchlist and check out 104 top founder-led companies
Bulls see Fluidra’s €40 million buyback and revenue of €1,303.22 million as support for the investment case, while bears point to the lower €125.89 million net income. Which side does the valuation currently lean toward?
Most Popular Narrative: 23.1% Undervalued
Fluidra's most followed narrative points to a fair value of €25.80 per share, compared with the recent close at €19.85, which frames the buyback within a broader rerating story.
Execution of operational efficiency initiatives, including the simplification program and strategic procurement, which are on track to deliver €100 million in targeted annual savings, are structurally lowering the cost base and setting the stage for further EBIT margin expansion, underpinning sustainable long-term earnings growth.
Want to see what that savings plan means for Fluidra's margin profile and earnings power? The full narrative lays out a detailed path for revenue, profitability and the valuation multiple that underpins this fair value view.
Result: Fair Value of €25.80 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Fluidra narrative still hinges on U.S. channel destocking and currency headwinds resolving, as these factors could otherwise pressure reported revenue and earnings for longer.
Find out about the key risks to this Fluidra narrative.
Another View on Fluidra’s Valuation
The first narrative leans on future earnings to argue Fluidra is 23.1% undervalued at €25.80 per share. The current share price of €19.85 sits against a P/E of 22.7x, which is higher than the European Machinery industry on 21x and well above the peer average of 12.5x.
However, Simply Wall St’s fair ratio for Fluidra is 26.6x. That is above the current 22.7x P/E, so the market could move closer to that level if earnings progress as expected. The question for you is whether paying more than industry and peer multiples feels like a risk worth taking for that potential re rating.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed picture on Fluidra has you unsure, it makes sense to review the facts quickly and decide where you stand on its potential. To weigh both the upside and the risks in one place, start with the 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Fluidra?
If Fluidra has sharpened your focus, now is the time to broaden your opportunity set and make sure you are not overlooking other compelling setups.
- Spot potential turnaround stories early by scanning 226 elite penny stocks with strong financials that already show stronger financial footing than many investors expect.
- Target quality at a sensible price and use 242 high quality undervalued stocks to surface stocks where fundamentals and valuation may be out of sync.
- Prioritise resilience in your portfolio by reviewing 298 resilient stocks with low risk scores that combine lower risk scores with more durable business profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com